nodes	percent_of_prediction	percent_of_DWPC	metapath
Clarithromycin—CYP3A4—bone cancer	0.648	1	CbGaD
Clarithromycin—SLC22A7—Methotrexate—bone cancer	0.0824	0.557	CbGbCtD
Clarithromycin—ABCB1—Cisplatin—bone cancer	0.024	0.163	CbGbCtD
Clarithromycin—ABCB1—Doxorubicin—bone cancer	0.0161	0.109	CbGbCtD
Clarithromycin—ABCB1—Methotrexate—bone cancer	0.0156	0.106	CbGbCtD
Clarithromycin—CYP3A4—Doxorubicin—bone cancer	0.00965	0.0653	CbGbCtD
Clarithromycin—Josamycin—CYP3A4—bone cancer	0.00233	0.296	CrCbGaD
Clarithromycin—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00165	0.0698	CbGpPWpGaD
Clarithromycin—Roxithromycin—CYP3A4—bone cancer	0.00126	0.16	CrCbGaD
Clarithromycin—Azithromycin—CYP3A4—bone cancer	0.00126	0.16	CrCbGaD
Clarithromycin—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00125	0.0526	CbGpPWpGaD
Clarithromycin—Telithromycin—CYP3A4—bone cancer	0.00123	0.155	CrCbGaD
Clarithromycin—Troleandomycin—CYP3A4—bone cancer	0.000969	0.123	CrCbGaD
Clarithromycin—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000901	0.038	CbGpPWpGaD
Clarithromycin—Erythromycin—CYP3A4—bone cancer	0.000841	0.107	CrCbGaD
Clarithromycin—SLC22A7—Fluoropyrimidine Activity—DHFR—bone cancer	0.000812	0.0343	CbGpPWpGaD
Clarithromycin—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000697	0.0294	CbGpPWpGaD
Clarithromycin—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000683	0.0288	CbGpPWpGaD
Clarithromycin—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00064	0.027	CbGpPWpGaD
Clarithromycin—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000639	0.027	CbGpPWpGaD
Clarithromycin—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000607	0.0256	CbGpPWpGaD
Clarithromycin—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000602	0.0254	CbGpPWpGaD
Clarithromycin—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000579	0.0244	CbGpPWpGaD
Clarithromycin—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000543	0.0229	CbGpPWpGaD
Clarithromycin—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000537	0.0227	CbGpPWpGaD
Clarithromycin—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000453	0.0191	CbGpPWpGaD
Clarithromycin—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000435	0.0184	CbGpPWpGaD
Clarithromycin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000419	0.0177	CbGpPWpGaD
Clarithromycin—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000418	0.0177	CbGpPWpGaD
Clarithromycin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000394	0.0166	CbGpPWpGaD
Clarithromycin—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000388	0.0164	CbGpPWpGaD
Clarithromycin—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000374	0.0158	CbGpPWpGaD
Clarithromycin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000367	0.0155	CbGpPWpGaD
Clarithromycin—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000336	0.0142	CbGpPWpGaD
Clarithromycin—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000323	0.0137	CbGpPWpGaD
Clarithromycin—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000313	0.0132	CbGpPWpGaD
Clarithromycin—Pneumonia—Epirubicin—bone cancer	0.000303	0.00176	CcSEcCtD
Clarithromycin—Infestation NOS—Epirubicin—bone cancer	0.000302	0.00175	CcSEcCtD
Clarithromycin—Infestation—Epirubicin—bone cancer	0.000302	0.00175	CcSEcCtD
Clarithromycin—Agranulocytosis—Methotrexate—bone cancer	0.000301	0.00175	CcSEcCtD
Clarithromycin—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.0003	0.0127	CbGpPWpGaD
Clarithromycin—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000299	0.00174	CcSEcCtD
Clarithromycin—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000299	0.0126	CbGpPWpGaD
Clarithromycin—Renal failure—Epirubicin—bone cancer	0.000297	0.00172	CcSEcCtD
Clarithromycin—Body temperature increased—Cisplatin—bone cancer	0.000296	0.00172	CcSEcCtD
Clarithromycin—Jaundice—Epirubicin—bone cancer	0.000294	0.00171	CcSEcCtD
Clarithromycin—Stomatitis—Epirubicin—bone cancer	0.000294	0.00171	CcSEcCtD
Clarithromycin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000293	0.0124	CbGpPWpGaD
Clarithromycin—Conjunctivitis—Epirubicin—bone cancer	0.000293	0.0017	CcSEcCtD
Clarithromycin—Dysuria—Doxorubicin—bone cancer	0.000293	0.0017	CcSEcCtD
Clarithromycin—Neutropenia—Doxorubicin—bone cancer	0.000293	0.0017	CcSEcCtD
Clarithromycin—Haemoglobin—Methotrexate—bone cancer	0.000291	0.00169	CcSEcCtD
Clarithromycin—Haemorrhage—Methotrexate—bone cancer	0.000289	0.00168	CcSEcCtD
Clarithromycin—Hepatitis—Methotrexate—bone cancer	0.000289	0.00168	CcSEcCtD
Clarithromycin—Haematuria—Epirubicin—bone cancer	0.000288	0.00167	CcSEcCtD
Clarithromycin—Pharyngitis—Methotrexate—bone cancer	0.000287	0.00167	CcSEcCtD
Clarithromycin—Urinary tract disorder—Methotrexate—bone cancer	0.000286	0.00166	CcSEcCtD
Clarithromycin—Hepatobiliary disease—Epirubicin—bone cancer	0.000285	0.00166	CcSEcCtD
Clarithromycin—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000285	0.012	CbGpPWpGaD
Clarithromycin—Epistaxis—Epirubicin—bone cancer	0.000285	0.00165	CcSEcCtD
Clarithromycin—Urethral disorder—Methotrexate—bone cancer	0.000284	0.00165	CcSEcCtD
Clarithromycin—Agranulocytosis—Epirubicin—bone cancer	0.000282	0.00163	CcSEcCtD
Clarithromycin—Pneumonia—Doxorubicin—bone cancer	0.000281	0.00163	CcSEcCtD
Clarithromycin—Infestation NOS—Doxorubicin—bone cancer	0.000279	0.00162	CcSEcCtD
Clarithromycin—Infestation—Doxorubicin—bone cancer	0.000279	0.00162	CcSEcCtD
Clarithromycin—Visual impairment—Methotrexate—bone cancer	0.000279	0.00162	CcSEcCtD
Clarithromycin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000277	0.00161	CcSEcCtD
Clarithromycin—Hypersensitivity—Cisplatin—bone cancer	0.000276	0.0016	CcSEcCtD
Clarithromycin—Renal failure—Doxorubicin—bone cancer	0.000274	0.00159	CcSEcCtD
Clarithromycin—Erythema multiforme—Methotrexate—bone cancer	0.000274	0.00159	CcSEcCtD
Clarithromycin—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000273	0.0115	CbGpPWpGaD
Clarithromycin—Haemoglobin—Epirubicin—bone cancer	0.000272	0.00158	CcSEcCtD
Clarithromycin—Stomatitis—Doxorubicin—bone cancer	0.000272	0.00158	CcSEcCtD
Clarithromycin—Jaundice—Doxorubicin—bone cancer	0.000272	0.00158	CcSEcCtD
Clarithromycin—Rhinitis—Epirubicin—bone cancer	0.000272	0.00158	CcSEcCtD
Clarithromycin—Conjunctivitis—Doxorubicin—bone cancer	0.000271	0.00157	CcSEcCtD
Clarithromycin—Hepatitis—Epirubicin—bone cancer	0.000271	0.00157	CcSEcCtD
Clarithromycin—Haemorrhage—Epirubicin—bone cancer	0.000271	0.00157	CcSEcCtD
Clarithromycin—Eye disorder—Methotrexate—bone cancer	0.00027	0.00157	CcSEcCtD
Clarithromycin—Tinnitus—Methotrexate—bone cancer	0.00027	0.00157	CcSEcCtD
Clarithromycin—Asthenia—Cisplatin—bone cancer	0.000269	0.00156	CcSEcCtD
Clarithromycin—Pharyngitis—Epirubicin—bone cancer	0.000269	0.00156	CcSEcCtD
Clarithromycin—Cardiac disorder—Methotrexate—bone cancer	0.000269	0.00156	CcSEcCtD
Clarithromycin—Urinary tract disorder—Epirubicin—bone cancer	0.000268	0.00155	CcSEcCtD
Clarithromycin—Haematuria—Doxorubicin—bone cancer	0.000266	0.00154	CcSEcCtD
Clarithromycin—Connective tissue disorder—Epirubicin—bone cancer	0.000266	0.00154	CcSEcCtD
Clarithromycin—Urethral disorder—Epirubicin—bone cancer	0.000266	0.00154	CcSEcCtD
Clarithromycin—Hepatobiliary disease—Doxorubicin—bone cancer	0.000264	0.00153	CcSEcCtD
Clarithromycin—Epistaxis—Doxorubicin—bone cancer	0.000263	0.00153	CcSEcCtD
Clarithromycin—Angiopathy—Methotrexate—bone cancer	0.000263	0.00152	CcSEcCtD
Clarithromycin—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000262	0.0111	CbGpPWpGaD
Clarithromycin—Immune system disorder—Methotrexate—bone cancer	0.000261	0.00152	CcSEcCtD
Clarithromycin—Visual impairment—Epirubicin—bone cancer	0.000261	0.00151	CcSEcCtD
Clarithromycin—Mediastinal disorder—Methotrexate—bone cancer	0.000261	0.00151	CcSEcCtD
Clarithromycin—Agranulocytosis—Doxorubicin—bone cancer	0.000261	0.00151	CcSEcCtD
Clarithromycin—Chills—Methotrexate—bone cancer	0.00026	0.00151	CcSEcCtD
Clarithromycin—Diarrhoea—Cisplatin—bone cancer	0.000256	0.00149	CcSEcCtD
Clarithromycin—Erythema multiforme—Epirubicin—bone cancer	0.000256	0.00149	CcSEcCtD
Clarithromycin—Mental disorder—Methotrexate—bone cancer	0.000254	0.00147	CcSEcCtD
Clarithromycin—Eye disorder—Epirubicin—bone cancer	0.000253	0.00147	CcSEcCtD
Clarithromycin—Tinnitus—Epirubicin—bone cancer	0.000253	0.00147	CcSEcCtD
Clarithromycin—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000252	0.0106	CbGpPWpGaD
Clarithromycin—Malnutrition—Methotrexate—bone cancer	0.000252	0.00146	CcSEcCtD
Clarithromycin—Haemoglobin—Doxorubicin—bone cancer	0.000252	0.00146	CcSEcCtD
Clarithromycin—Cardiac disorder—Epirubicin—bone cancer	0.000251	0.00146	CcSEcCtD
Clarithromycin—Flushing—Epirubicin—bone cancer	0.000251	0.00146	CcSEcCtD
Clarithromycin—Rhinitis—Doxorubicin—bone cancer	0.000251	0.00146	CcSEcCtD
Clarithromycin—Hepatitis—Doxorubicin—bone cancer	0.000251	0.00145	CcSEcCtD
Clarithromycin—Haemorrhage—Doxorubicin—bone cancer	0.000251	0.00145	CcSEcCtD
Clarithromycin—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00025	0.0105	CbGpPWpGaD
Clarithromycin—Pharyngitis—Doxorubicin—bone cancer	0.000249	0.00144	CcSEcCtD
Clarithromycin—Urinary tract disorder—Doxorubicin—bone cancer	0.000248	0.00144	CcSEcCtD
Clarithromycin—Dysgeusia—Methotrexate—bone cancer	0.000247	0.00143	CcSEcCtD
Clarithromycin—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000247	0.0104	CbGpPWpGaD
Clarithromycin—Connective tissue disorder—Doxorubicin—bone cancer	0.000246	0.00143	CcSEcCtD
Clarithromycin—Angiopathy—Epirubicin—bone cancer	0.000246	0.00143	CcSEcCtD
Clarithromycin—Urethral disorder—Doxorubicin—bone cancer	0.000246	0.00143	CcSEcCtD
Clarithromycin—Immune system disorder—Epirubicin—bone cancer	0.000245	0.00142	CcSEcCtD
Clarithromycin—Mediastinal disorder—Epirubicin—bone cancer	0.000244	0.00142	CcSEcCtD
Clarithromycin—Back pain—Methotrexate—bone cancer	0.000244	0.00141	CcSEcCtD
Clarithromycin—Chills—Epirubicin—bone cancer	0.000243	0.00141	CcSEcCtD
Clarithromycin—Visual impairment—Doxorubicin—bone cancer	0.000242	0.0014	CcSEcCtD
Clarithromycin—Vomiting—Cisplatin—bone cancer	0.000238	0.00138	CcSEcCtD
Clarithromycin—Mental disorder—Epirubicin—bone cancer	0.000237	0.00138	CcSEcCtD
Clarithromycin—Erythema multiforme—Doxorubicin—bone cancer	0.000237	0.00137	CcSEcCtD
Clarithromycin—Rash—Cisplatin—bone cancer	0.000236	0.00137	CcSEcCtD
Clarithromycin—Dermatitis—Cisplatin—bone cancer	0.000236	0.00137	CcSEcCtD
Clarithromycin—Malnutrition—Epirubicin—bone cancer	0.000236	0.00137	CcSEcCtD
Clarithromycin—Eye disorder—Doxorubicin—bone cancer	0.000234	0.00136	CcSEcCtD
Clarithromycin—Ill-defined disorder—Methotrexate—bone cancer	0.000234	0.00136	CcSEcCtD
Clarithromycin—Tinnitus—Doxorubicin—bone cancer	0.000234	0.00136	CcSEcCtD
Clarithromycin—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000234	0.00986	CbGpPWpGaD
Clarithromycin—Anaemia—Methotrexate—bone cancer	0.000233	0.00135	CcSEcCtD
Clarithromycin—Cardiac disorder—Doxorubicin—bone cancer	0.000233	0.00135	CcSEcCtD
Clarithromycin—Flushing—Doxorubicin—bone cancer	0.000233	0.00135	CcSEcCtD
Clarithromycin—Flatulence—Epirubicin—bone cancer	0.000232	0.00135	CcSEcCtD
Clarithromycin—Tension—Epirubicin—bone cancer	0.000231	0.00134	CcSEcCtD
Clarithromycin—Dysgeusia—Epirubicin—bone cancer	0.000231	0.00134	CcSEcCtD
Clarithromycin—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000231	0.00975	CbGpPWpGaD
Clarithromycin—Nervousness—Epirubicin—bone cancer	0.000229	0.00133	CcSEcCtD
Clarithromycin—Back pain—Epirubicin—bone cancer	0.000228	0.00132	CcSEcCtD
Clarithromycin—Angiopathy—Doxorubicin—bone cancer	0.000227	0.00132	CcSEcCtD
Clarithromycin—Malaise—Methotrexate—bone cancer	0.000227	0.00132	CcSEcCtD
Clarithromycin—Muscle spasms—Epirubicin—bone cancer	0.000227	0.00132	CcSEcCtD
Clarithromycin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000226	0.00956	CbGpPWpGaD
Clarithromycin—Immune system disorder—Doxorubicin—bone cancer	0.000226	0.00131	CcSEcCtD
Clarithromycin—Vertigo—Methotrexate—bone cancer	0.000226	0.00131	CcSEcCtD
Clarithromycin—Mediastinal disorder—Doxorubicin—bone cancer	0.000226	0.00131	CcSEcCtD
Clarithromycin—Leukopenia—Methotrexate—bone cancer	0.000226	0.00131	CcSEcCtD
Clarithromycin—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000225	0.00951	CbGpPWpGaD
Clarithromycin—Chills—Doxorubicin—bone cancer	0.000225	0.0013	CcSEcCtD
Clarithromycin—Nausea—Cisplatin—bone cancer	0.000223	0.00129	CcSEcCtD
Clarithromycin—Cough—Methotrexate—bone cancer	0.00022	0.00128	CcSEcCtD
Clarithromycin—Mental disorder—Doxorubicin—bone cancer	0.00022	0.00127	CcSEcCtD
Clarithromycin—Ill-defined disorder—Epirubicin—bone cancer	0.000219	0.00127	CcSEcCtD
Clarithromycin—Convulsion—Methotrexate—bone cancer	0.000218	0.00127	CcSEcCtD
Clarithromycin—Malnutrition—Doxorubicin—bone cancer	0.000218	0.00127	CcSEcCtD
Clarithromycin—Anaemia—Epirubicin—bone cancer	0.000218	0.00126	CcSEcCtD
Clarithromycin—Agitation—Epirubicin—bone cancer	0.000217	0.00126	CcSEcCtD
Clarithromycin—Flatulence—Doxorubicin—bone cancer	0.000215	0.00125	CcSEcCtD
Clarithromycin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000215	0.00906	CbGpPWpGaD
Clarithromycin—Chest pain—Methotrexate—bone cancer	0.000215	0.00124	CcSEcCtD
Clarithromycin—Myalgia—Methotrexate—bone cancer	0.000215	0.00124	CcSEcCtD
Clarithromycin—Tension—Doxorubicin—bone cancer	0.000214	0.00124	CcSEcCtD
Clarithromycin—Dysgeusia—Doxorubicin—bone cancer	0.000214	0.00124	CcSEcCtD
Clarithromycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000213	0.00124	CcSEcCtD
Clarithromycin—Malaise—Epirubicin—bone cancer	0.000213	0.00123	CcSEcCtD
Clarithromycin—Discomfort—Methotrexate—bone cancer	0.000212	0.00123	CcSEcCtD
Clarithromycin—Nervousness—Doxorubicin—bone cancer	0.000212	0.00123	CcSEcCtD
Clarithromycin—Vertigo—Epirubicin—bone cancer	0.000212	0.00123	CcSEcCtD
Clarithromycin—Leukopenia—Epirubicin—bone cancer	0.000211	0.00122	CcSEcCtD
Clarithromycin—Back pain—Doxorubicin—bone cancer	0.000211	0.00122	CcSEcCtD
Clarithromycin—Muscle spasms—Doxorubicin—bone cancer	0.00021	0.00122	CcSEcCtD
Clarithromycin—Palpitations—Epirubicin—bone cancer	0.000208	0.00121	CcSEcCtD
Clarithromycin—Confusional state—Methotrexate—bone cancer	0.000207	0.0012	CcSEcCtD
Clarithromycin—Loss of consciousness—Epirubicin—bone cancer	0.000207	0.0012	CcSEcCtD
Clarithromycin—Cough—Epirubicin—bone cancer	0.000206	0.00119	CcSEcCtD
Clarithromycin—Anaphylactic shock—Methotrexate—bone cancer	0.000206	0.00119	CcSEcCtD
Clarithromycin—Convulsion—Epirubicin—bone cancer	0.000204	0.00119	CcSEcCtD
Clarithromycin—Infection—Methotrexate—bone cancer	0.000204	0.00119	CcSEcCtD
Clarithromycin—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000203	0.00855	CbGpPWpGaD
Clarithromycin—Ill-defined disorder—Doxorubicin—bone cancer	0.000202	0.00117	CcSEcCtD
Clarithromycin—Nervous system disorder—Methotrexate—bone cancer	0.000202	0.00117	CcSEcCtD
Clarithromycin—Anaemia—Doxorubicin—bone cancer	0.000202	0.00117	CcSEcCtD
Clarithromycin—Thrombocytopenia—Methotrexate—bone cancer	0.000201	0.00117	CcSEcCtD
Clarithromycin—Chest pain—Epirubicin—bone cancer	0.000201	0.00116	CcSEcCtD
Clarithromycin—Myalgia—Epirubicin—bone cancer	0.000201	0.00116	CcSEcCtD
Clarithromycin—Agitation—Doxorubicin—bone cancer	0.000201	0.00116	CcSEcCtD
Clarithromycin—Anxiety—Epirubicin—bone cancer	0.0002	0.00116	CcSEcCtD
Clarithromycin—Skin disorder—Methotrexate—bone cancer	0.0002	0.00116	CcSEcCtD
Clarithromycin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000199	0.00116	CcSEcCtD
Clarithromycin—Hyperhidrosis—Methotrexate—bone cancer	0.000199	0.00115	CcSEcCtD
Clarithromycin—Discomfort—Epirubicin—bone cancer	0.000198	0.00115	CcSEcCtD
Clarithromycin—Malaise—Doxorubicin—bone cancer	0.000197	0.00114	CcSEcCtD
Clarithromycin—Dry mouth—Epirubicin—bone cancer	0.000196	0.00114	CcSEcCtD
Clarithromycin—Vertigo—Doxorubicin—bone cancer	0.000196	0.00114	CcSEcCtD
Clarithromycin—Anorexia—Methotrexate—bone cancer	0.000196	0.00114	CcSEcCtD
Clarithromycin—Leukopenia—Doxorubicin—bone cancer	0.000195	0.00113	CcSEcCtD
Clarithromycin—Confusional state—Epirubicin—bone cancer	0.000194	0.00113	CcSEcCtD
Clarithromycin—Palpitations—Doxorubicin—bone cancer	0.000193	0.00112	CcSEcCtD
Clarithromycin—Anaphylactic shock—Epirubicin—bone cancer	0.000192	0.00112	CcSEcCtD
Clarithromycin—Loss of consciousness—Doxorubicin—bone cancer	0.000192	0.00111	CcSEcCtD
Clarithromycin—Infection—Epirubicin—bone cancer	0.000191	0.00111	CcSEcCtD
Clarithromycin—Cough—Doxorubicin—bone cancer	0.00019	0.0011	CcSEcCtD
Clarithromycin—Convulsion—Doxorubicin—bone cancer	0.000189	0.0011	CcSEcCtD
Clarithromycin—Nervous system disorder—Epirubicin—bone cancer	0.000189	0.00109	CcSEcCtD
Clarithromycin—Thrombocytopenia—Epirubicin—bone cancer	0.000188	0.00109	CcSEcCtD
Clarithromycin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000187	0.00109	CcSEcCtD
Clarithromycin—Skin disorder—Epirubicin—bone cancer	0.000187	0.00108	CcSEcCtD
Clarithromycin—Hyperhidrosis—Epirubicin—bone cancer	0.000186	0.00108	CcSEcCtD
Clarithromycin—Insomnia—Methotrexate—bone cancer	0.000186	0.00108	CcSEcCtD
Clarithromycin—Chest pain—Doxorubicin—bone cancer	0.000186	0.00108	CcSEcCtD
Clarithromycin—Myalgia—Doxorubicin—bone cancer	0.000186	0.00108	CcSEcCtD
Clarithromycin—Anxiety—Doxorubicin—bone cancer	0.000185	0.00107	CcSEcCtD
Clarithromycin—Paraesthesia—Methotrexate—bone cancer	0.000185	0.00107	CcSEcCtD
Clarithromycin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000184	0.00107	CcSEcCtD
Clarithromycin—Discomfort—Doxorubicin—bone cancer	0.000184	0.00106	CcSEcCtD
Clarithromycin—Anorexia—Epirubicin—bone cancer	0.000183	0.00106	CcSEcCtD
Clarithromycin—Dyspnoea—Methotrexate—bone cancer	0.000183	0.00106	CcSEcCtD
Clarithromycin—Somnolence—Methotrexate—bone cancer	0.000183	0.00106	CcSEcCtD
Clarithromycin—Dry mouth—Doxorubicin—bone cancer	0.000182	0.00105	CcSEcCtD
Clarithromycin—SLC22A7—Fluoropyrimidine Activity—TP53—bone cancer	0.000181	0.00766	CbGpPWpGaD
Clarithromycin—Dyspepsia—Methotrexate—bone cancer	0.000181	0.00105	CcSEcCtD
Clarithromycin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000181	0.00762	CbGpPWpGaD
Clarithromycin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00018	0.00761	CbGpPWpGaD
Clarithromycin—Confusional state—Doxorubicin—bone cancer	0.00018	0.00104	CcSEcCtD
Clarithromycin—Decreased appetite—Methotrexate—bone cancer	0.000179	0.00104	CcSEcCtD
Clarithromycin—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000178	0.00752	CbGpPWpGaD
Clarithromycin—Anaphylactic shock—Doxorubicin—bone cancer	0.000178	0.00103	CcSEcCtD
Clarithromycin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000178	0.00103	CcSEcCtD
Clarithromycin—Fatigue—Methotrexate—bone cancer	0.000177	0.00103	CcSEcCtD
Clarithromycin—Infection—Doxorubicin—bone cancer	0.000177	0.00103	CcSEcCtD
Clarithromycin—Pain—Methotrexate—bone cancer	0.000176	0.00102	CcSEcCtD
Clarithromycin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000175	0.00102	CcSEcCtD
Clarithromycin—Nervous system disorder—Doxorubicin—bone cancer	0.000175	0.00101	CcSEcCtD
Clarithromycin—Thrombocytopenia—Doxorubicin—bone cancer	0.000174	0.00101	CcSEcCtD
Clarithromycin—Insomnia—Epirubicin—bone cancer	0.000174	0.00101	CcSEcCtD
Clarithromycin—Skin disorder—Doxorubicin—bone cancer	0.000173	0.001	CcSEcCtD
Clarithromycin—Paraesthesia—Epirubicin—bone cancer	0.000173	0.001	CcSEcCtD
Clarithromycin—Hyperhidrosis—Doxorubicin—bone cancer	0.000172	0.000999	CcSEcCtD
Clarithromycin—Dyspnoea—Epirubicin—bone cancer	0.000172	0.000995	CcSEcCtD
Clarithromycin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000171	0.00723	CbGpPWpGaD
Clarithromycin—Somnolence—Epirubicin—bone cancer	0.000171	0.000993	CcSEcCtD
Clarithromycin—Anorexia—Doxorubicin—bone cancer	0.00017	0.000985	CcSEcCtD
Clarithromycin—Feeling abnormal—Methotrexate—bone cancer	0.000169	0.000983	CcSEcCtD
Clarithromycin—Dyspepsia—Epirubicin—bone cancer	0.000169	0.000983	CcSEcCtD
Clarithromycin—Gastrointestinal pain—Methotrexate—bone cancer	0.000168	0.000976	CcSEcCtD
Clarithromycin—Decreased appetite—Epirubicin—bone cancer	0.000167	0.000971	CcSEcCtD
Clarithromycin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000166	0.000964	CcSEcCtD
Clarithromycin—Fatigue—Epirubicin—bone cancer	0.000166	0.000963	CcSEcCtD
Clarithromycin—Pain—Epirubicin—bone cancer	0.000165	0.000955	CcSEcCtD
Clarithromycin—Constipation—Epirubicin—bone cancer	0.000165	0.000955	CcSEcCtD
Clarithromycin—Urticaria—Methotrexate—bone cancer	0.000163	0.000948	CcSEcCtD
Clarithromycin—Body temperature increased—Methotrexate—bone cancer	0.000163	0.000943	CcSEcCtD
Clarithromycin—Abdominal pain—Methotrexate—bone cancer	0.000163	0.000943	CcSEcCtD
Clarithromycin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000162	0.000941	CcSEcCtD
Clarithromycin—Insomnia—Doxorubicin—bone cancer	0.000161	0.000934	CcSEcCtD
Clarithromycin—Paraesthesia—Doxorubicin—bone cancer	0.00016	0.000928	CcSEcCtD
Clarithromycin—Dyspnoea—Doxorubicin—bone cancer	0.000159	0.000921	CcSEcCtD
Clarithromycin—Feeling abnormal—Epirubicin—bone cancer	0.000159	0.00092	CcSEcCtD
Clarithromycin—Somnolence—Doxorubicin—bone cancer	0.000158	0.000918	CcSEcCtD
Clarithromycin—Gastrointestinal pain—Epirubicin—bone cancer	0.000157	0.000913	CcSEcCtD
Clarithromycin—Dyspepsia—Doxorubicin—bone cancer	0.000157	0.000909	CcSEcCtD
Clarithromycin—Decreased appetite—Doxorubicin—bone cancer	0.000155	0.000898	CcSEcCtD
Clarithromycin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000154	0.000892	CcSEcCtD
Clarithromycin—Fatigue—Doxorubicin—bone cancer	0.000154	0.000891	CcSEcCtD
Clarithromycin—Urticaria—Epirubicin—bone cancer	0.000153	0.000887	CcSEcCtD
Clarithromycin—Constipation—Doxorubicin—bone cancer	0.000152	0.000883	CcSEcCtD
Clarithromycin—Pain—Doxorubicin—bone cancer	0.000152	0.000883	CcSEcCtD
Clarithromycin—Body temperature increased—Epirubicin—bone cancer	0.000152	0.000883	CcSEcCtD
Clarithromycin—Abdominal pain—Epirubicin—bone cancer	0.000152	0.000883	CcSEcCtD
Clarithromycin—Hypersensitivity—Methotrexate—bone cancer	0.000152	0.000879	CcSEcCtD
Clarithromycin—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000148	0.00624	CbGpPWpGaD
Clarithromycin—Asthenia—Methotrexate—bone cancer	0.000148	0.000856	CcSEcCtD
Clarithromycin—Feeling abnormal—Doxorubicin—bone cancer	0.000147	0.000851	CcSEcCtD
Clarithromycin—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000146	0.00618	CbGpPWpGaD
Clarithromycin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000146	0.000845	CcSEcCtD
Clarithromycin—Pruritus—Methotrexate—bone cancer	0.000145	0.000844	CcSEcCtD
Clarithromycin—Hypersensitivity—Epirubicin—bone cancer	0.000142	0.000823	CcSEcCtD
Clarithromycin—Urticaria—Doxorubicin—bone cancer	0.000141	0.000821	CcSEcCtD
Clarithromycin—SLC22A7—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000141	0.00595	CbGpPWpGaD
Clarithromycin—Abdominal pain—Doxorubicin—bone cancer	0.000141	0.000817	CcSEcCtD
Clarithromycin—Body temperature increased—Doxorubicin—bone cancer	0.000141	0.000817	CcSEcCtD
Clarithromycin—Diarrhoea—Methotrexate—bone cancer	0.000141	0.000816	CcSEcCtD
Clarithromycin—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00014	0.00589	CbGpPWpGaD
Clarithromycin—Asthenia—Epirubicin—bone cancer	0.000138	0.000801	CcSEcCtD
Clarithromycin—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000138	0.00582	CbGpPWpGaD
Clarithromycin—Pruritus—Epirubicin—bone cancer	0.000136	0.00079	CcSEcCtD
Clarithromycin—Dizziness—Methotrexate—bone cancer	0.000136	0.000789	CcSEcCtD
Clarithromycin—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000135	0.00568	CbGpPWpGaD
Clarithromycin—Diarrhoea—Epirubicin—bone cancer	0.000132	0.000764	CcSEcCtD
Clarithromycin—Hypersensitivity—Doxorubicin—bone cancer	0.000131	0.000761	CcSEcCtD
Clarithromycin—Vomiting—Methotrexate—bone cancer	0.000131	0.000759	CcSEcCtD
Clarithromycin—Rash—Methotrexate—bone cancer	0.00013	0.000752	CcSEcCtD
Clarithromycin—Dermatitis—Methotrexate—bone cancer	0.00013	0.000751	CcSEcCtD
Clarithromycin—Headache—Methotrexate—bone cancer	0.000129	0.000747	CcSEcCtD
Clarithromycin—Asthenia—Doxorubicin—bone cancer	0.000128	0.000741	CcSEcCtD
Clarithromycin—Dizziness—Epirubicin—bone cancer	0.000127	0.000738	CcSEcCtD
Clarithromycin—Pruritus—Doxorubicin—bone cancer	0.000126	0.000731	CcSEcCtD
Clarithromycin—Vomiting—Epirubicin—bone cancer	0.000122	0.00071	CcSEcCtD
Clarithromycin—Nausea—Methotrexate—bone cancer	0.000122	0.000709	CcSEcCtD
Clarithromycin—Diarrhoea—Doxorubicin—bone cancer	0.000122	0.000707	CcSEcCtD
Clarithromycin—SLC22A7—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000122	0.00513	CbGpPWpGaD
Clarithromycin—Rash—Epirubicin—bone cancer	0.000121	0.000704	CcSEcCtD
Clarithromycin—Dermatitis—Epirubicin—bone cancer	0.000121	0.000703	CcSEcCtD
Clarithromycin—Headache—Epirubicin—bone cancer	0.000121	0.000699	CcSEcCtD
Clarithromycin—Dizziness—Doxorubicin—bone cancer	0.000118	0.000683	CcSEcCtD
Clarithromycin—Nausea—Epirubicin—bone cancer	0.000114	0.000663	CcSEcCtD
Clarithromycin—Vomiting—Doxorubicin—bone cancer	0.000113	0.000657	CcSEcCtD
Clarithromycin—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000113	0.00478	CbGpPWpGaD
Clarithromycin—Rash—Doxorubicin—bone cancer	0.000112	0.000651	CcSEcCtD
Clarithromycin—Dermatitis—Doxorubicin—bone cancer	0.000112	0.000651	CcSEcCtD
Clarithromycin—Headache—Doxorubicin—bone cancer	0.000112	0.000647	CcSEcCtD
Clarithromycin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000109	0.00459	CbGpPWpGaD
Clarithromycin—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000108	0.00454	CbGpPWpGaD
Clarithromycin—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000107	0.00453	CbGpPWpGaD
Clarithromycin—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000106	0.00448	CbGpPWpGaD
Clarithromycin—Nausea—Doxorubicin—bone cancer	0.000106	0.000614	CcSEcCtD
Clarithromycin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	9.35e-05	0.00395	CbGpPWpGaD
Clarithromycin—CYP3A7—Biological oxidations—GSTP1—bone cancer	9.2e-05	0.00388	CbGpPWpGaD
Clarithromycin—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	9.08e-05	0.00383	CbGpPWpGaD
Clarithromycin—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.82e-05	0.00372	CbGpPWpGaD
Clarithromycin—CYP3A5—Biological oxidations—CYP3A4—bone cancer	7.78e-05	0.00328	CbGpPWpGaD
Clarithromycin—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	7.67e-05	0.00324	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	7.65e-05	0.00323	CbGpPWpGaD
Clarithromycin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	7.25e-05	0.00306	CbGpPWpGaD
Clarithromycin—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	7.16e-05	0.00302	CbGpPWpGaD
Clarithromycin—CYP1A2—Phase II conjugation—GSTP1—bone cancer	6.85e-05	0.00289	CbGpPWpGaD
Clarithromycin—CYP3A5—Biological oxidations—GSTP1—bone cancer	6.65e-05	0.00281	CbGpPWpGaD
Clarithromycin—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	6.56e-05	0.00277	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.51e-05	0.00275	CbGpPWpGaD
Clarithromycin—CYP3A7—Metabolism—NDUFA12—bone cancer	6.45e-05	0.00272	CbGpPWpGaD
Clarithromycin—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	6.18e-05	0.00261	CbGpPWpGaD
Clarithromycin—CYP2C19—Biological oxidations—CYP3A4—bone cancer	6.01e-05	0.00254	CbGpPWpGaD
Clarithromycin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	5.96e-05	0.00252	CbGpPWpGaD
Clarithromycin—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	5.93e-05	0.0025	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.93e-05	0.0025	CbGpPWpGaD
Clarithromycin—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	5.58e-05	0.00235	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.4e-05	0.00228	CbGpPWpGaD
Clarithromycin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	5.38e-05	0.00227	CbGpPWpGaD
Clarithromycin—CYP3A7—Metabolism—NT5C3A—bone cancer	5.34e-05	0.00226	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.32e-05	0.00225	CbGpPWpGaD
Clarithromycin—CYP2C19—Biological oxidations—GSTP1—bone cancer	5.14e-05	0.00217	CbGpPWpGaD
Clarithromycin—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	5.07e-05	0.00214	CbGpPWpGaD
Clarithromycin—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.04e-05	0.00213	CbGpPWpGaD
Clarithromycin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.77e-05	0.00202	CbGpPWpGaD
Clarithromycin—CYP1A2—Biological oxidations—CYP3A4—bone cancer	4.68e-05	0.00198	CbGpPWpGaD
Clarithromycin—CYP3A5—Metabolism—NDUFA12—bone cancer	4.66e-05	0.00197	CbGpPWpGaD
Clarithromycin—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	4.62e-05	0.00195	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.51e-05	0.0019	CbGpPWpGaD
Clarithromycin—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.5e-05	0.0019	CbGpPWpGaD
Clarithromycin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.23e-05	0.00178	CbGpPWpGaD
Clarithromycin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.23e-05	0.00178	CbGpPWpGaD
Clarithromycin—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.01e-05	0.00169	CbGpPWpGaD
Clarithromycin—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	3.95e-05	0.00167	CbGpPWpGaD
Clarithromycin—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.88e-05	0.00164	CbGpPWpGaD
Clarithromycin—CYP3A5—Metabolism—NT5C3A—bone cancer	3.86e-05	0.00163	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism—NDUFA12—bone cancer	3.6e-05	0.00152	CbGpPWpGaD
Clarithromycin—ABCB1—Metabolism—NDUFA12—bone cancer	3.52e-05	0.00149	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.35e-05	0.00141	CbGpPWpGaD
Clarithromycin—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.09e-05	0.00131	CbGpPWpGaD
Clarithromycin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.05e-05	0.00129	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism—NT5C3A—bone cancer	2.99e-05	0.00126	CbGpPWpGaD
Clarithromycin—ABCB1—Metabolism—NT5C3A—bone cancer	2.91e-05	0.00123	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism—NDUFA12—bone cancer	2.81e-05	0.00119	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.48e-05	0.00105	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.39e-05	0.00101	CbGpPWpGaD
Clarithromycin—CYP3A7—Metabolism—ENO2—bone cancer	2.34e-05	0.000988	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism—NT5C3A—bone cancer	2.33e-05	0.000982	CbGpPWpGaD
Clarithromycin—CYP3A7—Metabolism—DHFR—bone cancer	2.17e-05	0.000917	CbGpPWpGaD
Clarithromycin—CYP3A4—Metabolism—NDUFA12—bone cancer	2.17e-05	0.000915	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.16e-05	0.00091	CbGpPWpGaD
Clarithromycin—CYP3A7—Metabolism—GNA11—bone cancer	2.03e-05	0.000857	CbGpPWpGaD
Clarithromycin—CYP3A7—Metabolism—CYP3A4—bone cancer	1.84e-05	0.000777	CbGpPWpGaD
Clarithromycin—CYP3A4—Metabolism—NT5C3A—bone cancer	1.8e-05	0.000758	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.7e-05	0.000716	CbGpPWpGaD
Clarithromycin—CYP3A5—Metabolism—ENO2—bone cancer	1.69e-05	0.000714	CbGpPWpGaD
Clarithromycin—CYP3A7—Metabolism—GSTP1—bone cancer	1.57e-05	0.000664	CbGpPWpGaD
Clarithromycin—CYP3A5—Metabolism—DHFR—bone cancer	1.57e-05	0.000663	CbGpPWpGaD
Clarithromycin—CYP3A5—Metabolism—GNA11—bone cancer	1.47e-05	0.000619	CbGpPWpGaD
Clarithromycin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.42e-05	0.000601	CbGpPWpGaD
Clarithromycin—CYP3A5—Metabolism—CYP3A4—bone cancer	1.33e-05	0.000562	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism—ENO2—bone cancer	1.31e-05	0.000552	CbGpPWpGaD
Clarithromycin—ABCB1—Metabolism—ENO2—bone cancer	1.28e-05	0.000539	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism—DHFR—bone cancer	1.21e-05	0.000512	CbGpPWpGaD
Clarithromycin—ABCB1—Metabolism—DHFR—bone cancer	1.18e-05	0.0005	CbGpPWpGaD
Clarithromycin—CYP3A5—Metabolism—GSTP1—bone cancer	1.14e-05	0.00048	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism—GNA11—bone cancer	1.13e-05	0.000479	CbGpPWpGaD
Clarithromycin—ABCB1—Metabolism—GNA11—bone cancer	1.11e-05	0.000467	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism—CYP3A4—bone cancer	1.03e-05	0.000434	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.02e-05	0.000432	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism—ENO2—bone cancer	1.02e-05	0.00043	CbGpPWpGaD
Clarithromycin—ABCB1—Metabolism—CYP3A4—bone cancer	1e-05	0.000424	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism—DHFR—bone cancer	9.46e-06	0.000399	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism—GNA11—bone cancer	8.84e-06	0.000373	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism—GSTP1—bone cancer	8.79e-06	0.000371	CbGpPWpGaD
Clarithromycin—ABCB1—Metabolism—GSTP1—bone cancer	8.58e-06	0.000362	CbGpPWpGaD
Clarithromycin—CYP3A7—Metabolism—PTGS2—bone cancer	8.15e-06	0.000344	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism—CYP3A4—bone cancer	8.01e-06	0.000338	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.97e-06	0.000337	CbGpPWpGaD
Clarithromycin—CYP3A4—Metabolism—ENO2—bone cancer	7.87e-06	0.000332	CbGpPWpGaD
Clarithromycin—CYP3A4—Metabolism—DHFR—bone cancer	7.3e-06	0.000308	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism—GSTP1—bone cancer	6.85e-06	0.000289	CbGpPWpGaD
Clarithromycin—CYP3A4—Metabolism—GNA11—bone cancer	6.82e-06	0.000288	CbGpPWpGaD
Clarithromycin—CYP3A5—Metabolism—PTGS2—bone cancer	5.89e-06	0.000249	CbGpPWpGaD
Clarithromycin—CYP3A4—Metabolism—GSTP1—bone cancer	5.29e-06	0.000223	CbGpPWpGaD
Clarithromycin—CYP2C19—Metabolism—PTGS2—bone cancer	4.56e-06	0.000192	CbGpPWpGaD
Clarithromycin—ABCB1—Metabolism—PTGS2—bone cancer	4.45e-06	0.000188	CbGpPWpGaD
Clarithromycin—CYP1A2—Metabolism—PTGS2—bone cancer	3.55e-06	0.00015	CbGpPWpGaD
Clarithromycin—CYP3A4—Metabolism—PTGS2—bone cancer	2.74e-06	0.000116	CbGpPWpGaD
